Smith & Nephew SNATS (NYSE:SNN) Stock Crosses Below 200 Day Moving Average - What's Next?

Smith & Nephew SNATS logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Smith & Nephew shares fell below their 200-day moving average, trading as low as $30.39 versus the average of $30.96; the stock last traded at $30.485, down 1.6%.
  • Analyst views are mixed, but the overall consensus is “Reduce”, based on one Buy, eight Hold, and two Sell ratings. The average price target is $31.91.
  • Institutional investors own 25.64% of the company’s shares, and several firms recently established or increased small positions.
  • Interested in Smith & Nephew SNATS? Here are five stocks we like better.

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report)'s share price passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $30.96 and traded as low as $30.39. Smith & Nephew SNATS shares last traded at $30.4850, with a volume of 1,411,956 shares changing hands.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SNN. Weiss Ratings cut shares of Smith & Nephew SNATS from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, September 24th. Wall Street Zen upgraded Smith & Nephew SNATS from a "hold" rating to a "buy" rating in a research note on Sunday. Zacks Research lowered Smith & Nephew SNATS from a "hold" rating to a "strong sell" rating in a report on Thursday, November 5th. Barclays cut Smith & Nephew SNATS from an "equal weight" rating to an "underweight" rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley cut Smith & Nephew SNATS from an "overweight" rating to an "equal weight" rating in a research note on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and an average target price of $31.91.

View Our Latest Stock Report on SNN

Smith & Nephew SNATS Stock Down 1.6%

The business's 50-day moving average is $28.82 and its two-hundred day moving average is $30.96. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14.

Hedge Funds Weigh In On Smith & Nephew SNATS

Institutional investors have recently made changes to their positions in the stock. Clearstead Trust LLC acquired a new stake in shares of Smith & Nephew SNATS in the 2nd quarter worth about $25,000. Ancora Advisors LLC lifted its position in Smith & Nephew SNATS by 235.6% in the 3rd quarter. Ancora Advisors LLC now owns 970 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 681 shares during the last quarter. Addison Advisors LLC bought a new stake in Smith & Nephew SNATS in the 2nd quarter valued at about $43,000. Allworth Financial LP bought a new stake in Smith & Nephew SNATS in the 2nd quarter valued at about $48,000. Finally, Parallel Advisors LLC boosted its stake in Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider's stock valued at $74,000 after purchasing an additional 387 shares during the period. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Company Profile

(Get Free Report)

Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair. Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Smith & Nephew SNATS Right Now?

Before you consider Smith & Nephew SNATS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.

While Smith & Nephew SNATS currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines